FDA
-
-
-
-
-
-
-
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
-
-
-
-
-
-
-
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
-
-
-
-
-
-
-
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
-
-
-
-
-
-
-
Imunon (IMNN) PT Raised to $14 at H.C. Wainwright
-
-
-
-
-
-
-
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
-
-
-
-
-
-
-
IMUNON Reports 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
-
323,590 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

